Citations

Clear

3030 citation(s) found for "Susan, M".

Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder
Kemp, David E. , Friedman, Edward S., Reilly-Harrington, Noreen A. , Sylvia, Louisa G. , Calabrese, Joseph R. , Rabideau, Dustin J. , Ketter, Terence A. , Thase, Michael E., Tohen, Mauricio , Bowden, Charles L., Brody, Benjamin D. , Deckersbach, Thilo , Kocsis, James H., Kinrys, Gustavo , Kamali, Masoud , McInnis, Melvin G. , Leon, Andrew C. , Faraone, Stephen V. , Nierenberg, Andrew A. , Shelton, Richard C. , McElroy, Susan L. , Singh, Vivek Kumar , Bernstein, Emily E. , Bobo, William V. , Kamali, Masoud , McInnis, Melvin G

Mayo Clinic

Acta Psychiatrica Scandinavica | June 26, 2015 | Volume: 133 | Issue: 2 | Pages: 144-153

10.1111/acps.12460 | PMID 26114830 Get It

ObjectiveExamine the effects of obesity and metabolic syndrome on outcome in bipolar disorder.MethodThe Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder (Bipolar CHOICE) study randomized 482 participants with bipolar disorder in a 6‐month trial comparing lithium‐ and quetiapine‐based treatment. Baseline variables were compared between groups with and without obesity, with and without abdominal obesity, and with and without metabolic syndrome respectively. The effects of baseline obesity, abdominal obesity, and metabolic syndrome on outcomes were examined using mixed effects linear regression models.ResultsAt baseline, 44.4% of participants had obesity, 48.0% had abdominal obesity, and 27.3% had metabolic syndrome; neither obesity, nor abdominal obesity, nor metabolic syndrome were associated with increased global severity, mood symptoms, or suicidality, or with poorer functioning or life satisfaction. Treatment groups did not differ on prevalence of obesity, abdominal obesity, or metabolic syndrome. By contrast, among the entire cohort, obesity was associated with less global improvement and less improvement in total mood and depressive symptoms, suicidality, functioning, and life satisfaction after 6 months of treatment. Abdominal obesity was associated with similar findings. Metabolic syndrome had no effect on outcome.ConclusionObesity and abdominal obesity, but not metabolic syndrome, were associated with less improvement after 6 months of lithium‐ or quetiapine‐based treatment.
Transient Apical Thickening Following Apical Ballooning Syndrome: A Case Series
Abudiab, Muaz M. , Wilansky, Susan , Lester, Steven J., Yousefzai, Rayan , Tyler, Rochelle, Tajik, A. Jamil

Mayo Clinic

Echocardiography | June 20, 2015 | Volume: 32 | Issue: 11 | Pages: 1723-1727

10.1111/echo.13001 | PMID 26096634 Get It

The authors describe transient apical thickening mimicking apical hypertrophic cardiomyopathy following apical ballooning syndrome. These findings are observed on multimodality cardiac imaging and appear to constitute a novel entity. Possible pathophysiologic mechanisms are explored.
Memory, executive, and multidomain subtle cognitive impairment
Toledo, Jon B. , Bjerke, Maria , Rozycki, Martin, Jack, Clifford R. , Weiner, Michael W. , Arnold, Steven E. , Reiman, Eric M. , Davatzikos, Christos , Shaw, Leslie M. , Trojanowski, John Q. , Initiative, For the Alzheimer's Disease Neuroimaging, Weiner, Michael, Aisen, Paul , Weiner, Michael, Petersen, Ronald, Jagust, William, Trojanowki, John Q., Green, Robert C., Saykin, Andrew J., Liu, Enchi , Green, Robert C., Montine, Tom, Petersen, Ronald, Gamst, Anthony, Thomas, Ronald G. , Walter, Sarah , Gessert, Devon, Sather, Tamie, Kornak, John , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene E. , DeCarli, Charles, Jagust, William, Bandy, Dan, Foster, Norm, Reiman, Eric M., Mathis, Chet, Cairns, Nigel J. , Taylor‐Reinwald, Lisa, Shaw, Les, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Potkin, Steven, Kachaturian, Zaven, Frank, Richard , Molchan, Susan, Quinn, Joseph, Lind, Betty, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Petersen, Ronald, Johnson, Kris , Doody, Rachelle S., Chowdhury, Munir , Bell, Karen L. , Leon, Sue, Schneider, Stacy, Marson, Daniel , Griffith, Randall, Clark, David, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varon, Daniel, Roberts, Peggy, Albert, Marilyn, Onyike, Chiadi, Kielb, Stephanie , Glodzik, Lidia , Santi, Susan De , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Coleman, R. Edward, Arnold, Steven E., Karlawish, Jason , Smith, Charles D., Jicha, Gregory A. , Hardy, Peter , Oakley, MaryAnn, Simpson, Donna M., Goldstein, Bonnie S., Martin, Kim, Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Mathews, Dana, Quiceno, Mary , King, Richard, Weiner, Myron, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Apostolova, Liana , Lu, Po H. , Bartzokis, George, Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin R. , Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Mudge, Benita, Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Mesulam, Marek-Marsel, Lipowski, Kristina, Wu, Chuang‐Kuo, Johnson, Nancy , Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen, Reynolds, Brigid, Johnson, Keith A. , Marshall, Gad A. , Frey, Meghan , Yesavage, Jerome A. , Taylor, Joy L. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Sabbagh, Marwan N. , Belden, Christine M. , Jacobson, Sandra A. , Kowall, Neil W. , Budson, Andrew E. , Johnson, Patricia Lynn, Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Olichney, John , Kittur, Smita, Borrie, Michael, Lee, T‐Y, Bartha, Dr Rob, Asthana, Sanjay , Carlsson, Cynthia M., Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Saykin, Andrew J., Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Garg, Pradeep , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J. , Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Rachinsky, Irina, Rogers, John, Kertesz, Andrew, Drost, Dick, Hernando, Raymundo, Sarrael, Antero, Schultz, Susan K. , Ponto, Laura L. Boles , Shim, Hyungsub , Smith, Karen E. , Relkin, Norman , Chaing, Gloria, Raudin, Lisa, Smith, Amanda , Fargher, Kristin, Raj, Balebail Ashok, Chen, Kewei , Initiative, For the Alzheimer's Disease Neuroimaging, Weiner, Michael, Weiner, Michael, Petersen, Ronald, Jagust, William, Toga, Arthur W. , Beckett, Laurel , Green, Robert C., Saykin, Andrew J., Morris, John C. , Green, Robert C., Petersen, Ronald, Donohue, Michael , Harvey, Danielle , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Jagust, William, Koeppe, Robert A. , Foster, Norm, Reiman, Eric M., Mathis, Chet, Lee, Virginia M.‐Y. , Saykin, Andrew J. , Foroud, Tatiana , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Lord, Joanne L. , Petersen, Ronald, Villanueva-Meyer, Javier E. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Shah, Raj C. , Duara, Ranjan , Varón, Daniel , Rusinek, Henry , Leon, Mony J. de , Arnold, Steven E., Wolk, David A. , López, Oscar L. , Porsteinsson, Anton P. , Womack, Kyle , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Black, Sandra E. , Stefanovic, Bojana , Feldman, Howard , Kertesz, Andrew, Rogers, John, Kerwin, Diana , Martínez, Walter Fabián , Turner, Raymond Scott , Sperling, Reisa Anne , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Carmichael, Owen , Johnson, Sterling C. , Carlsson, Cynthia M. , Potkin, Steven G. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Pearlson, Godfrey D. , Saykin, Andrew J., Sink, Kaycee M. , Miller, Bruce L. , Finger, Elizabeth C. , Rogers, John, Kertesz, Andrew, Jack, Clifford R , Preda, Adrian , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Neurology | June 18, 2015 | Volume: 85 | Issue: 2 | Pages: 144-153

10.1212/wnl.0000000000001738 | PMID 26085606 Get It

Impact of Freezing Time and Balloon Size on the Thermodynamics and Isolation Efficacy During Pulmonary Vein Isolation Using the Second Generation Cryoballoon
Takami, Mitsuru , Misiri, Juna, Parker, Kay D., Sarmiento, Ray I., Johnson, Susan B., Packer, Douglas L. , Lehmann, H. Immo

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | June 17, 2015 | Volume: 8 | Issue: 4 | Pages: 836-845

10.1161/circep.115.002725 | PMID 26082516 Get It

Background— The differences in ablation characteristics of freezing time and balloon size using second generation cryoballoon are still unknown. Methods and Results— Twenty-six dogs underwent pulmonary vein (PV) isolation. Balloon and tissue temperatures (left atrial–PV junction, phrenic nerve, and internal esophagus) were monitored. The ablation duration was randomized to either 3 or 4 minutes, which did not show significant differences in temperature profiles, PV isolation success rate, complications, or histological changes. Twenty dogs underwent cryoablation using 28-mm cryoballoon, 6 dogs were done using the 23-mm cryoballoon. Positioning of the 23-mm cryoballoon was more distal in the PV, which resulted in better PV occlusion. Temperature profiles showed lower temperatures in the 23-mm cryoballoon than in the 28-mm cryoballoon (inner balloon, median [range]: −51.5 [−66.0 to −31.0] versus −43.0 [−64.0 to −26.0]°C, P <0.001; balloon surface: −43.0 [−60.0 to −15.8] versus −6.5 [−46.2 to 28.9]°C, P <0.001; left atrial–PV junction: −6.7 [−20.0 to 21.4] versus 15.8 [−14.4 to 35.1]°C, P <0.001), and trended toward a higher PV isolation success rate in the 23-mm cryoballoon. Histologically, deeper extensions of ablative lesions into the PV were seen with 23-mm cryoballoon, and larger ablative lesions were seen in the left atrial antrum using 28-mm cryoballoon. Conclusions— The efficacy of 3-minute ablation was not significantly different from 4-minute ablation in dogs. The 23-mm cryoballoon had a greater cooling effect than the 28-mm cryoballoon for small PVs, but showed narrower ablative lesions in the left atrial antrum.
Direct Pulmonary Vein Ablation With Stenosis Prevention Therapy
Holmes, David R. , Ebrille, Elisa , Syed, Faisal F. , Ladewig, Dorothy J., Mikell, Susan B. , Powers, Joanne, Suddendorf, Scott H., Gilles, Emily J., Danielsen, Andrew J., Hodge, David O. , Asirvatham, Samuel J. , Kapa, Suraj , DeSimone, Christopher V. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 15, 2015 | Volume: 26 | Issue: 9 | Pages: 1000-1006

10.1111/jce.12732 | PMID 26075706 Get It

Direct Pulmonary Vein Ablation With Stenosis Prevention TherapyIntroductionThe dominant location of electrical triggers for initiating atrial fibrillation (AF) originates from the muscle sleeves inside pulmonary veins (PVs). Currently, radiofrequency ablation (RFA) is performed outside of the PVs to isolate, rather than directly ablate these tissues, due to the risk of intraluminal PV stenosis.MethodsIn 4 chronic canine experiments, we performed direct PV muscle sleeve RFA ± postablation drug‐coated balloon (DCB) treatment with paclitaxel/everolimus. Of the 4 PVs, 2 PVs were ablated and treated with DCB, 1 PV was ablated without DCB treatment (positive control), and 1 PV was left as a negative control. Local electrograms were assessed in PVs for near‐field signals and were targeted for ablation. After 12–14 weeks survival, PVs were interrogated for absence of near‐field PV potentials, and each PV was assessed for stenosis.ResultsAll canines survived the study period without cardiorespiratory complications, and remained ambulatory. In all canines, PVs that were ablated and treated with DCB remained without any significant intraluminal stenosis. In contrast, PVs that were ablated and not treated with DCB showed near or complete intraluminal stenosis. At terminal study, PV potentials remained undetectable. A blinded, histologic analysis demonstrated that ablated PVs without DCB treatment had extensive thrombus, fibrin, mineralization, and elastin disruption.ConclusionOur chronic canine data suggest that direct PV tissue ablation without subsequent stenosis is feasible with the use of postablation DCBs.
Association between history of psychosis and cardiovascular disease in bipolar disorder
Prieto, Miguel L. , Sutor, Bruce, Kung, Simon , Cuéllar‐Barboza, Alfredo B. , Ösby, Urban, Chauhan, Mohit , Westman, Jeanette , Geske, Jennifer R. , Colby, Colin , Ryu, Euijung , Frye, Mark A. , Bobo, William V. , Colby, Colin L., McElroy, Susan L. , Hayes, Sharonne N. , Fuentes, Manuel Enrique , Crow, Scott J. , Biernacka, Joanna M. , Cuellar-Barboza, Alfredo , Geske, Jennifer , Chauhan, Mohit

Mayo Clinic

Bipolar Disorders | June 11, 2015 | Volume: 17 | Issue: 5 | Pages: 518-527

10.1111/bdi.12302 | PMID 26062406 Get It

ObjectivesTo determine whether clinical features of bipolar disorder, such as history of psychosis, and cardiovascular disease (CVD) risk factors contribute to a higher risk of CVD among patients with bipolar disorder.MethodsThis cross‐sectional study included a sample of 988 patients with bipolar I or bipolar II disorder or schizoaffective bipolar type confirmed by the Structured Clinical Interview for DSM‐IV‐TR disorders (SCID). Medical comorbidity burden was quantified utilizing the Cumulative Illness Severity Rating Scale (CIRS). This 13‐item organ‐based scale includes cardiac disease severity quantification. Confirmed by medical record review, patients who scored 1 (current mild or past significant problem) or higher in the cardiac item were compared by logistic regression to patients who scored 0 (no impairment), adjusting for CVD risk factors that were selected using a backwards stepwise approach or were obtained from the literature.ResultsIn a multivariate model, age [odds ratio (OR) = 3.03, 95% confidence interval (CI): 1.66–5.54, p < 0.0001], hypertension (OR = 2.43, 95% CI: 1.69–3.55, p < 0.0001), and history of psychosis (OR = 1.48, 95% CI: 1.03–2.13, p = 0.03) were associated with CVD. When CVD risk factors from the literature were added to the analysis, age (OR = 3.19, 95% CI: 1.67–6.10, p = 0.0005) and hypertension (OR = 2.46, 95% CI: 1.61–3.76, p < 0.01) remained significant, with psychosis being at the trend level (OR = 1.43, 95% CI: 0.96–2.13, p = 0.08).ConclusionsThe phenotype of psychotic bipolar disorder may reflect higher illness severity with associated cardiac comorbidity. Further studies are encouraged to clarify the effect of the disease burden (i.e., depression), lifestyle, and treatment interventions (i.e., atypical antipsychotics) on this risk association.
Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African and European Americans: The North Carolina-Louisiana Prostate Cancer Project (PCaP)
Antwi, Samuel O. , Su, L. Joseph , Zhang, Hongmei , Fontham, Elizabeth T. H., Smith, Gary J., Bensen, Jeannette T. , Mohler, James L. , Arab, Lenore , Steck, Susan E. , Hébert, James R. , Antwi, Samuel O

Mayo Clinic

The Prostate | June 5, 2015 | Volume: 75 | Issue: 13 | Pages: 1419-1435

10.1002/pros.23025 | PMID 26053590 Get It

Chromosome X Genomic and Epigenomic Aberrations and Clinical Implications in Breast Cancer by Base Resolution Profiling
Sun, Zhifu , Prodduturi, Naresh, Sun, Susan , Thompson, E. Aubrey , Kocher, Jean‐Pierre , Sun, Zhifu

Mayo Clinic

Epigenomics | June 3, 2015 | Volume: 7 | Issue: 7 | Pages: 1099-1110

10.2217/epi.15.43 | PMID 26039248 Get It

HepPar-1 and Arginase-1 Immunohistochemistry in Adenocarcinoma of the Small Intestine and Ampullary Region
Lagana, Stephen M. , Hsiao, Susan J. , Bao, Fei , Sepulveda, Antonia R. , Moreira, Roger K. , Lefkowitch, Jay H., Remotti, Helen , Lagana, Stephen

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 2, 2015 | Volume: 139 | Issue: 6 | Pages: 791-795

10.5858/arpa.2013-0249-oa | PMID 26030248 Get It

Context HepPar-1 and Arginase-1 are urea cycle enzymes used to distinguish hepatocellular carcinoma from other carcinomas. HepPar-1, but not Arginase-1, is known to be immunoreactive with normal human small intestine. Objectives To better define and compare the immunohistochemical staining patterns of HepPar-1 and Arginase-1 in adenocarcinomas arising in the small intestine, including the ampullary region. Design Staining for HepPar-1 and Arginase-1 was performed on 20 nonampullary small intestinal adenocarcinomas and 32 adenocarcinomas from the ampullary region. Ampullary adenocarcinomas were divided into intestinal morphology (15), pancreatobiliary morphology (14), and unclassifiable (3). Nonneoplastic small intestinal mucosa and colorectal adenocarcinomas were used as control groups. Results HepPar-1 stained 12 of 20 nonampullary small intestinal adenocarcinomas, with a median of 63% of cells staining in positive cases. It also stained 11 of 15 ampullary carcinomas with intestinal morphology, with a median of 75% of cells staining in positive cases. Two of 14 ampullary carcinomas with pancreatobiliary morphology were positive for HepPar-1. Arginase-1 showed positivity in 2 ampullary region carcinomas and diffuse positivity in 1 duodenal adenocarcinoma. Two of 22 colorectal carcinomas stained for HepPar-1 with none positive for Arginase-1. Conclusions HepPar-1, but not Arginase-1, usually shows positivity in small intestinal adenocarcinomas and ampullary adenocarcinomas with intestinal morphology, but only rarely shows positivity in ampullary adenocarcinomas with pancreatobiliary morphology. HepPar-1 positivity in metastatic adenocarcinoma with intestinal morphology is suggestive of an upper gastrointestinal primary site.
Altruistic reasoning in adolescent-parent dyads considering participation in a hypothetical sexual health clinical trial for adolescents
Chávez, Noé Rubén , Williams, Camille Y. , Ipp, Lisa, Catallozzi, Marina , Rosenthal, Susan L. , Breitkopf, Carmen Radecki

Mayo Clinic

Research Ethics | May 27, 2015 | Volume: 12 | Issue: 2 | Pages: 68-79

10.1177/1747016115587963 | PMID 27019669 Get It

Altruism is a well-established reason underlying research participation. Less is known about altruism in adolescent-parent decision-making about clinical trials enrolling healthy adolescents. This qualitative investigation focused on identifying spontaneous statements of altruism within adolescent-parent (dyadic) discussions of participation in a hypothetical phase I clinical trial related to adolescent sexual health. Content analysis revealed several response patterns to each other’s altruistic reasoning. Across 70 adolescent-parent dyads in which adolescents were 14 to 17 years of age and 91% of their parents were mothers, a majority (61%) of dyadic discussions included a statement reflecting altruism. Parents responded to adolescents’ statements of altruism more frequently than adolescents responded to parents’ statements. Responses included: expresses concern, reiterates altruistic reasoning, agrees with altruistic reasoning, and adds to/expands altruistic reasoning. Since an altruistic perspective was often balanced with concerns about risk or study procedures, researchers cannot assume that altruism will directly lead to study participation. Optimizing the informed consent process for early phase clinical trials involving healthy adolescents may include supporting parents to have conversations with their adolescents which will enhance their capacity to consider all aspects of trial participation.